Skip to main navigation

Codiak Biosciences

Investor Relations - Top Nav

Our Science
Our Science

Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.
Manufacturing
Pipeline & Programs
Pipeline & Programs

We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.
About Us
About Us

At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.
Careers
Investors & Media
Investors & Media

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

Press Releases

Year

April 10, 2021

Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer Immunotherapy Pathways

Additional Formats

PDF Version

March 17, 2021

Codiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

Additional Formats

PDF Version

March 10, 2021

Codiak to Present Data from Two Novel Engineered Exosome Therapeutic Candidate Programs at the American Association for Cancer Research (AACR) Annual Meeting

Additional Formats

PDF Version

February 17, 2021

Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ Option

Additional Formats

PDF Version

February 11, 2021

Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock

Additional Formats

PDF Version

February 9, 2021

Codiak Announces Proposed Public Offering of Common Stock

Additional Formats

PDF Version

February 4, 2021

Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients

Additional Formats

PDF Version

January 21, 2021

Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy

Additional Formats

PDF Version

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2021 All Rights Reserved.

Footer Links

Contact
Privacy Policy
Terms of Use

LinkedIn Twitter